ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints
(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and
Read more